Improved comfort and patient acceptance in a novel transdermal nitroglycerin delivery system.
Sixty-three angina patients were recruited to participate in a two-week, randomized, open-label, crossover, multicenter trial to compare patient acceptance of two transdermal nitroglycerin delivery systems, Minitran and Transderm-Nitro (TDN). Patients were enrolled if they had stable angina and had been on a stabilized dose (5, 10, or 15 mg/24 hr) of Nitro-Dur II (ND II) for at least one month before entering the study. Patients with a bias against TDN or with any of the contraindications for transdermal nitroglycerin therapy were excluded. During the two consecutive one-week treatment periods, the patients received their prestudy dose regimen of Minitran and TDN in random order. Patients completed daily diaries, weekly questionnaires, and poststudy patient preference evaluation forms. Of the 63 patients who completed the study, 70% preferred Minitran overall (P less than or equal to 0.001), 24% preferred TDN, and 6% had no overall preference.
Hougham
A J
AJ
3M Riker, St. Paul, Minnesota.
Hawkinson
R W
RW
Crowley
J K
JK
Wilson
R R
RR
Brown
S G
SG
Dougherty
P J
PJ
Fogel
M A
MA
Hash
V W
VW
Rietbrock
M J
MJ
D000268:Adhesiveness; D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007509:Irritants; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage* / Q000009:adverse effects; D010342:Patient Acceptance of Health Care
D007509:Irritants; D005996:Nitroglycerin